Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules
AI Sentiment
Positive
7/10
as of 12-12-2025 4:00pm EST
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | DOYLESTOWN |
| Market Cap: | 6.9M | IPO Year: | 2019 |
| Target Price: | $20.00 | AVG Volume (30 days): | 71.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.14 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.90 - $5.00 | Next Earning Date: | 11-12-2025 |
| Revenue: | $488,239 | Revenue Growth: | -62.75% |
| Revenue Growth (this year): | -80.92% | Revenue Growth (next year): | N/A |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
SrVP/CFO/Prin Fin & Acct Ofcr
Avg Cost/Share
$1.17
Shares
5,000
Total Value
$5,825.00
Owned After
27,733
SEC Form 4
APRE Breaking Stock News: Dive into APRE Ticker-Specific Updates for Smart Investing
AI Sentiment
Positive
7/10
See how APRE stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "APRE Aprea Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.